drugset
drugset / Trial / NCT05042375

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

NCT05042375 ↗

Phase 3 Unknown 450 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate vs. pembrolizumab in treatment naïve subjects with programmed death-ligand 1(PD-L1)-positive recurrent or metastatic non-small cell lung cancer (NSCLC).

Timeline

Start
2022-09-08
Primary completion
2023-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg —
Subject Famitinib Small molecule 20 mg —
Subject Pembrolizumab Monoclonal antibody 200 mg —

Indications

non-small cell lung carcinoma